# Central Drugs Standard Control Organisation (CDSCO)

Type: organization

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/central-drugs-standard-control-organisation-cdsco
Canonical HTML page: https://gethealthbrief.com/entity/central-drugs-standard-control-organisation-cdsco

## Timeline

- **2030-12-31**: Target Milestone — Goal to reach $50 billion market size and 10-12% global market share.
- **2026-03-17**: Contempt Notice Issued — Justice Sachin Datta issues formal notice to CDSCO seeking an explanation for the delay.
- **2026-03-15T05:15:37Z**:  — Rollout of Production Linked Incentive schemes for high-end medical equipment.
- **2026-03-15**: Chintan Shivir — Department of Commerce holds strategic brainstorming to boost exports.
- **2026-02**: Contempt Petition Filed — Petitioners move court alleging CDSCO failed to meet the review deadline.
- **2025-Q3**: Initial Court Order — Delhi HC directs CDSCO to evaluate safety of diabetes drugs for weight loss.
- **2023-05-01**: Policy Launch — National Medical Device Policy 2023 is officially notified.

## Recent coverage (3 stories)

### Eli Lilly’s Rs 2.15 lakh cancer pill enters India: Will precision oncology widen the equity gap?
2026-06-26 01:54:12 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

Eli Lilly's RET inhibitor Tanstrive hits the Indian market at Rs 2.15 lakh per 14-day course, promising targeted therapy for advanced solid tumors but raising urgent questions about affordability, insurance coverage, and diagnostic capacity in the country's strained healthcare system.
Full story: https://gethealthbrief.com/story/tanstrive-india-launch-access-cost

### Delhi High Court Issues Contempt Notice to CDSCO Over Weight-Loss Drug Delay
2026-03-18 00:52:56 · Sentiment: Bearish · Impact: 6/10 · Sources: 2

The Delhi High Court has issued a contempt notice to India's drug regulator, CDSCO, for failing to comply with judicial orders to evaluate the safety of diabetes drugs used off-label for weight loss. This escalation signals a growing legal intolerance for regulatory delays amidst a global surge in GLP-1 receptor agonist demand.
Full story: https://gethealthbrief.com/story/delhi-hc-contempt-notice-cdsco-diabetes-weight-loss

### India Targets Global Medical Device Leadership via Chintan Shivir Strategy
2026-03-15 05:15:37 · Sentiment: Bullish · Impact: 6/10 · Sources: 4

The Indian Department of Commerce has convened a 'Chintan Shivir' to overhaul the nation's medical device export framework. This strategic brainstorming session aims to address regulatory hurdles and incentivize domestic manufacturing to position India as a global med-tech hub.
Full story: https://gethealthbrief.com/story/india-medical-device-export-chintan-shivir

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.